Sleeping sickness

Clinical Microbiology and Infection

Volumn 17, Issue 7, 2011, Pages 986-995

  Malvy, D ^a,b   Chappuis, F ^c,d  

^a University Hospital Centre   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Human African trypanosomiasis; Review; Sleeping sickness; Trypanosoma brucei gambiense; Trypanosoma brucei rhodesiense; Tsetse

Indexed keywords

EFLORNITHINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; MELARSOPROL; NIFURTIMOX; PENTAMIDINE ISETHIONATE; SURAMIN; TUMOR NECROSIS FACTOR ALPHA;

AFRICA; AFRICAN TRYPANOSOMIASIS; BONE MARROW TOXICITY; BRAIN DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MACROPHAGE; MORBIDITY; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHLEBITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RASH; REVIEW; SCLEROSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA GAMBIENSE;

ANIMALIA; GLOSSINA (GENUS); PROTOZOA; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 79959947843     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03536.x     Document Type: Review

References (59)

1. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011; 5: e1007.
2. Balasegaram M, Balasegaram S, Malvy D, Millet P. Neglected diseases in the news: a content analysis of recent international media coverage focussing on leishmaniasis and trypanosomiasis. PLoS Negl Trop Dis 2008; 2: e234.
3. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 2010; 375: 148-159.
4. Cattand P, Jannin JG, Lucas P. Sleeping sickness surveillance: an essential step towards elimination. Trop Med Int Health 2001; 6: 348-361.
5. Fèvre EM, Wissmann BV, Weburn SC, Lutumba P. The burden of human African trypanosomiasis. PLoS Negl Trop Dis 2008; 2: e333.
6. Courtin F, Jamonneau V, Duvallet G et al. Sleeping sickness in West Africa (1906-2006): changes in spatial repartition and lessons from the past. Trop Med Int Health 2008; 133: 334-344.
7. Vanhaecke C, Guevart E, Ezzedine K et al. Human African trypanosomiasis in mangrove epidemiologic area. Presentation, diagnosis and treatment in Guinea, 2005-2007. Pathol Biol 2010; 58: 110-116.
8. Courtin F, Sidibé L, Rouamba J, Jamonneau V, Gouro A, Solano P. Population growth and global warming: impacts on tsetse and trypanosomiasis in West Africa. Parasite 2009; 16: 3-10.
9. Simarro PP, Cecchi G, Paone M et al. The atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 2010; 9: 57.
10. Joshi PP, Shegovar VR, Powar RM et al. Human trypanosomiasis caused by Trypanosoma evansi in India: the first case report. Am J Trop Med Hyg 2005; 73: 491-495.
11. Barrett MP. The rise and fall of sleeping sickness. Lancet 2006; 367: 1377-1378.
12. Chappuis F, Lima MA, Flevaud L, Ritmeijer K. Human African trypanosomiasis in areas without surveillance. Emerg Infect Dis 2010; 16: 354-356.
13. WHO. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec 2006; 8: 71-80.
14. Vincendeau P, Bouteille B. Immunology and immunopathology of African trypanosomiasis. An Acad Bras Cienc 2006; 78: 645-665.
15. Semballa S, Geffard M, Daulouède S et al. Antibodies directed against nitrosylated neoepitopes in sera of patients with human African trypanosomiasis. Trop Med Int Health 2004; 9: 1104-1110.
16. Vincendeau P, Gobert AP, Daulouède S, Moynet D, Mossalayi MD. Arginases in parasitic diseases. Trends Parasitol 2003; 19: 9-12.
17. Mamani-Matsuda M, Rambert J, Malvy D et al. Quercetin induces apoptosis of Trypanosoma brucei gambiense and decreases the proinflammatory response of human macrophages. Antimicrob Agents Chemother 2004; 48: 924-929.
18. Checci F, Filipe JA, Haydon DT, Chandramohan D, Chappuis F. Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis 2008; 8: 16.
19. Blum JA, Burri C, Hatz C, Kazumba L, Mangoni P, Zellweger MJ. Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis). Trop Med Int Health 2007; 12: 1422-1432.
20. Kennedy PG. Human African trypanosomiasis-neurological aspects. J Neurol 2006; 253: 411-416.
21. Bedat-Millet AL, Charpentier S, Monge SMF, Woimant F. Psychiatric presentation of human African trypanosomiasis: overview of diagnostic pitfalls, interest of difluoromethylornithine treatment and contribution of magnetic resonance imaging. Rev Neurol (Paris) 2000; 156: 505-509.
22. Truc P, Tibayrenc M. Population genetics of Trypanosoma brucei in central Africa: taxonomic and epidemiological significance. Parasitology 1993; 106: 137-149.
23. Jamonneau V, Garcia A, Ravel S et al. Genetic characterization of Trypanosoma brucei gambiense and clinical evolution of human African trypanosomiasis in Côte d'Ivoire. Trop Med Int Health 2002; 7: 610-621.
24. Blum J, Beck BR, Brun R, Hatz C. Clinical and serological responses to human 'apathogenic' trypanosomes. Trans R Soc Trop Med Hyg 2005; 99: 795-797.
25. Chappuis F, Loutan L, Simarro P, Lejon V, Buscher P. Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev 2005; 18: 133-146.
26. Lejon V, Boelaert M, Jannin J, Moore A, Buscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis 2003; 3: 804-808.
27. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. b. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978; 58: 169-176.
28. Chappuis F, Stivanello E, Adams K, Kidane S, Pittet A, Bovier PA. Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African Trypanosomiasis (Trypanosoma brucei gambiense) among serologically suspected individuals in southern Sudan. Am J Trop Med Hyg 2004; 71: 313-317.
29. Simarro PP, Ruiz JA, Franco JR, Josenando T. Attitude towards CATT-positive individuals without parasitological confirmation in the African trypanosomiasis (T. b. gambiense) focus of Quicama (Angola). Trop Med Int Health 1999; 4: 858-861.
30. Woo PT. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop 1970; 27: 384-386.
31. Truc P, Jamonneau V, N'Guessan P, Diallo PB, Garcia A. Parasitological diagnosis of human African trypanosomiasis: a comparison of the OBC and miniature anion-exchange centrifugation techniques. Trans R Soc Trop Med Hyg 1998; 92: 288-289.
32. Lutumba P, Robays J, Miaka C et al. Validity, cost and feasibility of the mAECT and CTC confirmation tests after diagnosis of African of sleeping sickness. Trop Med Int Health 2006; 11: 470-478.
33. Buscher P, Mumba Ngoyi D, Kabore J et al. Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for sleeping sickness diagnosis and staging. PLoS Negl Trop Dis 2009; 3: e471.
34. Lutumba P, Meheus F, Robays J et al. Cost-effectiveness of algorithms for confirmation test of human African trypanosomiasis. Emerg Infect Dis 2007; 13: 1484-1490.
35. Lejon V, Buscher P. Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health 2005; 10: 395-403.
36. Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 2010; 137: 1987-1994.
37. Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, Checchi F. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontières programmes. Trans R Soc Trop Med Hyg 2009; 103: 280-290.
38. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41: 748-751.
39. Priotto G, Kasparian S, Mutombo W et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374: 56-64.
40. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355: 1419-1425.
41. Kuepfer I. Proceedings of the 30th Meeting of the International Scientific Council for Trypanosomiasis Research and Control, 2009, Kampala, Uganda.
42. Mumba Ngoyi D, Lejon V, Pyana P et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2010; 201: 453-463.
43. Malvy D, Djossou F, Longy-Boursier M, Le Bras M, Weill FX, Chapuis P. Human West African trypanosomiasis with chancre presentation. Eur J Dermatol 2000; 10: 561-562.
44. Gautret P, Clerinx J, Caumes E et al. Imported human African trypanosomiasis in Europe, 2005-2009. Euro Surveill 2009; 14: 4-6.
45. Ezzedine K, Darie H, Le Bras M, Malvy D. Skin features accompanying imported human African trypanosomiasis: hemolymphatic Trypanosoma brucei gambiense infection among two French expatriates with dermatologic manifestations. J Travel Med 2007; 14: 192-196.
46. Duggan AL, Hutchinson MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg 1966; 69: 124-131.
47. Spencer HCJ, Gibson JJ Jr, Brodsky RE, Schultz MG. Imported African trypanosomiasis in the United States. Ann Intern Med 1975; 82: 633-638.
48. Jelinek T, Bisoffi Z, Bonazzi L et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 2002; 8: 634-635.
49. Nadim B, Van Tulleken C, Mac Donald D, Chiodini PL. East African trypanosomiasis in a pregnant traveler. Emerg Infect Dis 2009; 15: 1866-1867.
50. Moore DA, Edwards M, Escombe R et al. African trypanosomiasis in travellers returning to the United Kingdom. Emerg Infect Dis 2002; 8: 74-76.
51. Health Protection Agency. African trypanosomiais (sleeping sickness) in a traveller visiting Zimbabwe and Zambia, Health Protection Report. 22 Ocober 2010. Available at: (last accessed 22 October 2010).
52. ProMED-mail. Trypanosomiasis-USA ex Zambia: (Eastern). ProMED-mail 2010; 15 Sept: 20100915.3338. Available at: (last accessed 22 October 2010).
53. Moore AL, Ryan ET, Waldron MA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercices. Case 20-2002. A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa. N Engl J Med 2002; 346: 2069-2076.
54. Sholdt IL, Schreck CE, Mwangelwa MI, Nondo J, Stachinji VJ. Evaluations of permethrin-impregnated clothing and three topical repellent formulations of DEET against tsetse flies in Zambia. Med Vet Entomol 1989; 3: 153-158.
55. Receveur MC, Le Bras M, Vincendeau P. Laboratory-acquired Gambian trypanosomiasis. N Engl J Med 1993; 329: 209-210.
56. Simarro PP, Jannin JG, Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 2008; 5: 174-180.
57. Challier A, Laveissière C. The control of the vectors of the sleeping sickness caused by Trypanosoma gambiense. Med Trop 1978; 38: 697-703.
58. WHO. WHO Programme to eliminate sleeping sickness-building a global alliance. Geneva: World Health Organization, 2002.
59. African Union. Statement from the Commission of the African union to the AHP/DFID special workshop on: tsetse control-the next 100years, September 9-10, 2002, Edinburgh, UK.